Skip to Main ContentSkip to FooterSkip to Search
Main menu
  1. Home
  2.  » 
  3. Events
  4.  » Plasmid DNA and Advanced Therapies: Accelerating Path to Clinic

Plasmid DNA and Advanced Therapies: Accelerating Path to Clinic

Date: December 8, 2022
Time: 14:00 CET/ 13:00 GMT/ 08:00 EST

Webinar in collaboration with BioWin

 

Abstract

Gene therapies and emerging biomodalities are developing at an unprecedented pace, improving the lives of patients around the world. The high demand for those treatments opens a competitive market in which faster and high-quality cost-effective solutions are a clear advantage. The starting point for advanced therapies is generally DNA in the shape of plasmid DNA (pDNA). GMP requirements from early stage, together with the right tools and analytics providing the highest quality standards for pDNA, will ensure successful downstream applications as AAV, from early clinical development to commercial phase.

Join this webinar for an in-depth discussion of the challenges cell and gene therapy innovators face and how experts resolve these barriers through adopting technology and strategy that drive an optimized plasmid production process and supply. 

 

Key learning objectives

  1. Learn the current plasmid DNA manufacturing landscape.
  2. Discuss key considerations during plasmid production, including design and screening system and processing.
  3. Discuss main challenges linked to GMP pDNA production and the impact on different advanced therapy programs.

 

FEATURED SPEAKERS

 

Eli Keshavarz-Moore, MSc, Ph.D, FIChemE, CEng
Professor of Bioprocess Science and Enterprise, Department of Biochemical Engineering, University College London

 

 

About the speaker:

The central theme of Prof. Eli Keshavarz-Moore’s research has been to investigate the interaction between cell engineering and fermentation and downstream processing. The early focus was on the impact of recombinant technology on the processing of macromolecules; in particular proteins with specific attention to the way fermentation strategy may control the location of the protein, and its titre in order to adapt the best harvesting strategy and enable the provision of generic process options for downstream separation. Her research has been the basis for further study on creating a framework for rapid choice of a whole bioprocess prior to detailed design. She brought a new theme based on the specific, knowledge-based design of cells and their propagation in bioreactors in response to the needs and demands of downstream/ purification stages.

 

 

Nuria Gomez Santos, Ph.D
Head of Process & Analytical Development, pDNA

 

 

About the speaker:

Dr. Gomez Santos is the Head of Process and Analytical Development for plasmid DNA at Catalent Gene Therapy. With a strong expertise in molecular biology and microbiology, acquired throughout international experience in different research institutions for more than 15 years, she has developed her career in plasmid DNA bioproduction during the last 4 years. Nuria holds two BSc, one in Biology and another in Biochemistry, a MSc in Biotechnology and a Ph.D. in Microbiology.

 

MODERATOR

 

Thierry Ferain,
Director Innovation & Growth, BioWin

 

 

About the speaker:

Thierry Ferain, Ph.D. is Director Innovation & Growth at BioWin, the Health Cluster of Wallonia (Belgium), responsible for managing existing and future R&D projects in BioWin’s portfolio, with a special focus on programs dealing with (bio)pharma Drug Discovery & Development, Advanced Therapy Medicinal Products (ATMPs) and biomanufacturing digitalization.

After having spent several years in academic environment where he managed research activities in Molecular Biology and student supervision, he continued his career in the private sector through a collaborative program between UCL and Eurogentec. He then joined the Research and Development Unit of Euroscreen (taken over by Ogeda and later Astellas) and was responsible for managing several internal projects as well as collaborative projects with Belgian and foreign companies and laboratories. These opportunities have allowed him to develop strong skills in team management, scientific communication, development and coordination of collaborative projects.

Thierry has more than 20 years’ experience in life sciences and holds a Ph.D. Degree in Biological Sciences from the Catholic University of Louvain (UCL).

About BioWin:

BioWin is the Health Cluster of Wallonia, Belgium. We are the regional reference holder for all stakeholders in innovative R&I projects in health biotechnology and medical technologies, whether they are companies, research centers or universities. We also aim to promote Wallonia internationally as a world-class life sciences environment for academic, clinical and industrial research.